Lidbree (Lidocaine)

Lidocaine blocks voltage‑gated sodium channels on nerve fibers, preventing the rapid influx of sodium ions needed for depolarization. This action stops the transmission of pain signals from the uterine tissue, producing a reversible loss of sensation while preserving muscle function.

The specific dose of Lidbree is determined by the prescribing clinician based on the type of uterine procedure, patient characteristics, and institutional protocols. Healthcare professionals calculate the appropriate volume and concentration to achieve effective local anesthesia while minimizing systemic exposure.

Safety data for intrauterine lidocaine during pregnancy are limited. Clinicians should weigh the potential benefits against any risks and consider alternative pain‑management strategies when treating pregnant or breastfeeding patients. Consultation with obstetric specialists is recommended.

To request Lidbree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Lidbree’s active ingredient, lidocaine, is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for short‑to‑moderate procedures. Compared with ester‑type anesthetics, lidocaine generally offers a lower risk of allergic reactions and a well‑characterized safety profile, though choice of agent depends on clinician preference and specific procedural requirements.

Lidbree should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures. Ensure the container is tightly closed when not in use and follow standard aseptic handling procedures during preparation.

Lidbree is administered directly into the uterine cavity by a qualified healthcare professional. The solution is typically injected through a catheter or syringe after the cervix is dilated, allowing the anesthetic to diffuse across the endometrial lining before the start of the procedure.

Serious risks include systemic lidocaine toxicity, which can manifest as seizures, cardiac arrhythmias, or severe hypotension, and rare allergic reactions such as anaphylaxis. Methemoglobinemia and prolonged numbness are also possible but uncommon. Prompt recognition and supportive care are essential if these events occur.

Lidbree should be avoided in individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, patients with severe cardiac conduction disorders, and those with significant hepatic impairment that could affect drug metabolism. Clinicians should also exercise caution in pregnant women and in patients receiving interacting medications.